3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Hyperglycemia
1
Hereditary Sensory and Autonomic Neuropathies
1
Diabetes Mellitus, Type 2
1
Diabetes Mellitus
1
Breast Neoplasms
1
Interventions
Fulvestrant
9
Alpelisib
6
Letrozole
4
serabelisib
3
ribociclib
3
palbociclib
3
duvelisib
3
berzosertib
3
Paclitaxel
3
PX-866
3
Cetuximab
3
sapanisertib
2
pembrolizumab
2
parsaclisib
2
binimetinib
2
Topotecan
2
NVP-BKM120
2
Irinotecan
2
Gemcitabine
2
venetoclax
1
tipifarnib
1
talazoparib
1
sotorasib
1
ruxolitinib
1
olaparib
1
obinutuzumab
1
niraparib
1
lorlatinib
1
liposomal doxorubicin
1
gedatolisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hereditary Sensory and Autonomic Neuropathies
×
dapagliflozin
×
Clear all
NCT04899349
2024-10-09
EPIK-B4
Novartis
Phase 2
Terminated
2 enrolled
8 charts